Item 2.02 - Results of Operations and Financial Condition: The filing reports STERIS plc's financial results and operational performance as of August 5, 2026 Item 2.03 - Cost Associated with Exit or Disposal Activities: The filing discloses costs related to exit or disposal activities undertaken by the company Item 9.01 - Financial Statements and Exhibits: The filing includes financial statements…

Our analysis rates this filing CAUTIOUS. The elevated concern level of 6.8/10 reflects a company navigating significant near-term headwinds while executing a major multi-year restructuring. The primary concerns are: (1) a material $55-70M restructuring commitment with 4-year execution risk spanning…

Concern level: HIGH (6.8/10). Key factors: Major facility consolidation with $55-70M restructuring charges and 4-year execution timeline through fiscal 2030 creates material financial and operational risk; Undisclosed 'EO litigation' explicitly flagged as potential threat to product introductions, production, supply, marketing, and financial performance with no details provided; Geopolitical and…

Notable risk changes: Announced $55-70 million restructuring plan to consolidate formulated chemistries manufacturing to new North Carolina Center of Excellence, with closure of St. Louis and Plymouth facilities; execution risk spans 4 years through fiscal 2030; Explicit disclosure of pending 'EO litigation' with potential to delay product introductions, impact production/supply/marketing, and affect financial…

The model predicts STE will underperform the S&P 500 by about 0.0% over 30 days (model confidence 65%). This is model analysis for research, not investment advice.